Form 4: Ginkgo Bioworks Executive Steven P. Coen Reports Stock Transactions

Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., reports acquisition and disposal of Class A Common Stock and Restricted Stock Units to cover tax obligations.

Summary

• On February 3, 2025, Steven P. Coen, Chief Accounting Officer of Ginkgo Bioworks Holdings, Inc., acquired 587 shares of Class A Common Stock and 156 shares of Class A Common Stock upon the vesting of Restricted Stock Units (RSUs).
• Also on February 3, 2025, Coen's holdings increased by 587 RSUs and 156 RSUs.
• On February 4, 2025, Coen disposed of 367 shares of Class A Common Stock at a price of $13.443 per share.
• These transactions were reported on a Form 4 filing with the SEC.
• The sales were to cover tax withholding obligations related to the vesting of restricted stock and/or restricted stock units and do not represent discretionary trades.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency in insider trading activities.
• Similar filings are made by executives at companies like Amyris and Zymergen (now Ginkgo Bioworks), reflecting stock transactions related to compensation and tax obligations.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership of shares.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates